scholarly journals Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD

Cancer ◽  
2011 ◽  
Vol 118 (14) ◽  
pp. 3565-3570 ◽  
Author(s):  
Anthony R. Mato ◽  
Jakub Svoboda ◽  
Tatyana Feldman ◽  
Tania Zielonka ◽  
Harry Agress ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Post Treatment ◽  
Emission Tomography ◽  
Computed Tomography Scan ◽  
Positron Emission ◽  
Mantle Cell ◽  
Tomography Scan

Interim and Post-Treatment Positron Emission Tomography-Computed Tomography Scan Status Is Highly Predictive Of Outcome In Diffuse Large Cell Lymphoma Patients Treated With R-CHOP21

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4294-4294
Author(s):  
Honghui Huang ◽  
Fei Xiao ◽  
Fangyuan Chen ◽  
Xiaofeng Han ◽  
Lu Zhong ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Cell Lymphoma ◽  
Post Treatment ◽  
Pet Scan ◽  
Emission Tomography ◽  
Computed Tomography Scan ◽  
Interim Pet ◽  
Positron Emission ◽  
Tomography Scan

Abstract Background Taking a step forward from the international prognostic index, attention is focused on the role of 18F-fluorodeoxyglucose positron-emission tomography-Computed Tomography scan (PET) as a tool for guidance in risk stratification in patients with diffuse large B-cell lymphoma (DLBCL). Here, we analyzed the predictive value of interim and post-treatment PET in patients with DLBCL. Methods In our retrospective study, we analyzed a homogeneous cohort of newly diagnosed DLBCL patients treated with R-CHOP21 who underwent PET scan at diagnosis, after three cycles of chemotherapy and at the end of treatment. For interim PET, images were interpreted by computing maximum standardized uptake value between PET performed at baseline and after three cycles of immuno-chemotherapy (¦¤SUVmax). The images of post-treatment PET were interpreted visually according to the International Harmonization Project criteria. The primary study endpoints were progression-free survival (PFS) and overall survival (OS). Results Thirty-eight patients with DLBCL with PET data were identified. The median follow-up was 28 months. At interim PET evaluation, optimal cutoff to predict progression was 66% for ¦¤SUVmax. ¦¤SUVmax analysis (≥66% vs< 66%) identified patients with significantly different 2-year PFS (90.7% vs 38.9%; P =.000) and 2-year OS (95.5% vs 62%; P=.016) (Fig1). Post-treatment PET status (negative vs positive) was statistically significantly associated with 2-year PFS (91% vs 45.5%; P =.001) and 2-year OS (100% vs 72.7%; P =.012) (Fig2). Conclusions These data support the prognostic utility of PET in interim and post-treatment settings in patients with DLBCL treated with R-CHOP21. An interim PET scan after three cycles of treatment can effectively predict the outcome by using quantitative assessment of ¦¤SUVmax and allows clinicians to design a risk-adapted therapeutic strategy. A positive PET after the completion of therapy identifies a patient subset with an inferior PFS and OS. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document